Rational Approaches for the Design of Effective Human Immunodeficiency Virus Type 1 Nonnucleoside Reverse Transcriptase Inhibitors

被引:11
作者
Ribone, Sergio R. [1 ]
Quevedo, Mario A. [1 ]
Madrid, Marcela [1 ]
Brinon, Margarita C. [2 ]
机构
[1] Univ Nacl Cordoba, Fac Ciencias Quim, Dept Farm, RA-5000 Cordoba, Argentina
[2] Pittsburgh Supercomp Ctr, Pittsburgh, PA 15213 USA
基金
美国国家科学基金会;
关键词
DRUG-RESISTANCE; POSITIONAL ADAPTABILITY; HIGHLY POTENT; HIV-1; RT; RILPIVIRINE; MECHANISMS; ETRAVIRINE; DISCOVERY; DOCKING; BINDING;
D O I
10.1021/ci1001636
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The binding of several classes of nonnucleoside reverse transcriptase inhibitors (NNRTIs) to wild-type (wtRT) and K103N mutant (mRT) human immunodeficiency virus type 1 (HIV-1) reverse transcriptase is studied by molecular dynamics and energy decomposition techniques. The imidoylthiourea (ITU), diaryltriazine (DATA), and diarylpyrimidine (DAPY) NNRTIs studied maintain the hydrogen bond with Lys101 during the 3 ns molecular dynamics trajectories. When bound to mRT, all the DAPYs studied establish hydrogen bonds with Glu138; among these, those of the potent inhibitors TMC120 and TMC125 are water-mediated. The molecular interactions of the NNRTIs in the binding pocket are correlated to the drugs' potency. Quantitative free energy analyses show a linear relationship between the van der Waals energetic component and the potency against wtRT. The molecular basis of the interaction between NNRTIs and RT presented here provide quantitative approaches for the design of novel effective anti-HIV drugs.
引用
收藏
页码:130 / 138
页数:9
相关论文
共 50 条
  • [21] Similarities and differences in the RNase H activities of human immunodeficiency virus type 1 reverse transcriptase and moloney murine leukemia virus reverse transcriptase
    Gao, HQ
    Sarafianos, SG
    Arnold, E
    Hughes, SH
    JOURNAL OF MOLECULAR BIOLOGY, 1999, 294 (05) : 1097 - 1113
  • [22] Advances in diarylpyrimidines and related analogues as HIV-1 nonnucleoside reverse transcriptase inhibitors
    Gu, Shuang-Xi
    Lu, Huan-Huan
    Liu, Gen-Yan
    Ju, Xiu-Lian
    Zhu, Yuan-Yuan
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 158 : 371 - 392
  • [23] Mechanisms of HIV-1 drug resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors
    G. N. Nikolenko
    A. T. Kotelkin
    S. F. Oreshkova
    A. A. Ilyichev
    Molecular Biology, 2011, 45 : 93 - 109
  • [24] Mechanisms of HIV-1 drug resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors
    Nikolenko, G. N.
    Kotelkin, A. T.
    Oreshkova, S. F.
    Ilyichev, A. A.
    MOLECULAR BIOLOGY, 2011, 45 (01) : 93 - 109
  • [25] Intrapatient Evolutionary Dynamics of Human Immunodeficiency Virus Type 1 in Individuals Undergoing Alternative Treatment Strategies with Reverse Transcriptase Inhibitors
    Kayondo, Jonathan K.
    Ndembi, Nicaise
    Parry, Chris M.
    Cane, Patricia A.
    Hue, Stephane
    Goodall, Ruth
    Dunn, David T.
    Kaleebu, Pontiano
    Pillay, Deenan
    Mbisa, Jean L.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2015, 31 (07) : 749 - 756
  • [26] Highly efficient inhibition of human immunodeficiency virus type 1 reverse transcriptase by aptamers functionalized gold nanoparticles
    Shiang, Yen-Chun
    Ou, Chung-Mao
    Chen, Shih-Ju
    Ou, Ting-Yu
    Lin, Han-Jia
    Huang, Chih-Ching
    Chang, Huan-Tsung
    NANOSCALE, 2013, 5 (07) : 2756 - 2764
  • [28] Dipyridodiazepinone Analogs as Human Immunodeficiency Virus Type 1-Specific Non-Nucleoside Reverse Transcriptase Inhibitors: An Overview
    Lv, M.
    Xu, H.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (18) : 1874 - 1898
  • [29] p53 enhances the fidelity of DNA synthesis by human immunodeficiency virus type 1 reverse transcriptase
    Bakhanashvili, M
    ONCOGENE, 2001, 20 (52) : 7635 - 7644
  • [30] The interaction of the reverse transcriptase of human immunodeficiency virus type 1 with 3'-terminally mispaired DNA
    Bakhanashvili, M
    Hizi, A
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1996, 334 (01) : 89 - 96